Quantum Surgical at the heart of a €14.9 million European project for precision cancer treatment
· Quantum Surgical is part of the PreciseOnco public-private partnership that unites experts from industry, research organizations, medical societies and leading European hospitals.
· Co-funded by the EU’s Innovative Health Initiative(IHI), the research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and enhance the precision of minimallyinvasive cancer treatments
· Five-year research program includes five clinical studies to validate the technical solutions
Montpellier, France – Quantum Surgical today announced that it joined the PreciseOnco consortium, which has been awarded funding from the EU’s Innovative Health Initiative (IHI) to advance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies. The EUR 14.9 million public funding will be complemented by EUR 9 million in in-kind contributions and additional resources from industry partners, supporting afive-year research and innovation program that also includes five clinical studies.
Quantum Surgical, a company specializing in robotics and AI, is developing the Epione® robotic-assisted percutaneous ablation platform. It assists physicians in planning trajectories, positioning treatment needles, and confirming adequate margins have been taken, in order to facilitate and standardize these minimally invasive procedures. Through this research project, Quantum Surgical will explore how Epione can further support spectral-guided interventional procedures.
“We are extremely excited to take part in the PreciseOnco project and to work alongside such prestigious partners to improve cancer care” says Bertin Nahum, President and Co-founder of Quantum Surgical. “We are delighted that Quantum Surgical’s expertise and capabilities can help enhance the precision of minimally invasive cancer treatments”.
Innovation public-private partnership
The PreciseOnco public-private partnership unites experts from industry, research organizations, medical societies and leading European hospitals:
· Industry partners: Philips, Quantum Surgical, and IGEA.
· Research organization: European Institute for Biomedical Imaging Research (EIBIR)
· Medical society: Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
· Academic partners: University Hospital Cologne (Uniklinik Koeln) in Germany, University Medical Center Utrecht (UMCU) and Leiden University Medical Center (LUMC) in the Netherlands, and two major university hospital networks in France: Assistance Publique–Hôpitaux de Paris (APHP; Hôpital Henri-Mondor) and Hospices Civils de Lyon (HCL).
By uniting Europe’s leading clinical expertise and industry innovation, PreciseOnco aims to set a new benchmark for precision, safety, and efficiency in minimally invasive cancer care.
The rising cancer burden and precision treatment needs
Cancer remains a leading health challenge, with approximately 2.7 million new diagnoses in Europe each year [1] with projections suggesting over 35 million new cancer cases globally by 2050, representing a 77% increase from 2022 [2]. In response to this growing challenge, interventional oncology has emerged as a rapidly evolving discipline that integrates medical imaging, oncology, and minimally invasive treatment approaches [3]. Such treatments - including targeted ablation, radioembolization, and electrochemotherapy - offer advantages over traditional surgery, such as shorter recovery times and fewer side effects; however, their effectiveness strongly depends on the performance of medical imaging and the precision with which physicians can guide instruments to tumors.
Bringing advanced technology into the interventional room
The PreciseOnco consortium aims to develop asuite of integrated technologies designed to take the next leap in precision cancer care. Central to the research and innovation program is spectral imaging, an advanced form of CT and cone-beam CT that captures significantly richer information about tissue composition than conventional imaging, enabling more confident differentiation between tumors, vasculature, and healthy tissue. By analyzing X-rays at different energy levels, spectral imaging enables physicians with greater clarity to see exactly what tissues they are treating.
To complement this advanced imaging technology, PreciseOnco will integrate robotic guidance systems that use real-time imaging data to guide interventional instruments (one or multiple needles) with sub-millimeter precision. The consortium will also look to advance electrochemotherapy, a minimally invasive technique that combines locally administered electrical pulses with chemotherapy to selectively treat cancer tissue, with the aim of maximizing tumor control while preserving surrounding healthy tissue.
Crucially, all these technologies will be powered by AI algorithms designed to enhance image quality, reduce radiation dose, streamline advanced visualization software and provide real time intraprocedural feedback on treatment success. This would allow physicians to confirm that tumors have been fully treated before the patient leaves the operating room.
Clinical studies
The project is structured into multiple work packages covering spectral imaging technology development, AI based image processing, robotic guidance integration, multi-center clinical validation, and health economic assessment. PreciseOnco will conduct five clinical studies spanning multiple cancer types and interventional workflows, ensuring robust validation in real world clinical settings:
· VISTA (Virtual Spectral Imaging for Superior Thermal Ablation Guidance): Evaluating spectral imaging to improve liver, kidney ablation procedures andliver radioembolization.
· SPOT ON (Spectral angiography-computed tomography to Optimize percutaneous Tumor ablation): Assessing spectral CT for better tumor targeting and treatment planning.
· HORA EST HCC 2: Combining thermal ablation with transarterial chemoembolization (TACE) in a single session for improved hepatocellular carcinoma treatment.
· SPECTRA-L (Spectral Performance Evaluation of a CT-Equipped Therapeutic RadiologyAngio Suite in Liver): Testing spectral imaging for transarterial chemoembolization (TACE) procedures.
· LASER (Locoregional therApies Spectral Evaluation of Responses): Develop ingimaging biomarkers to predict treatment success across multiple cancer typesand interventional techniques.
Together, these studies will generate evidence to support the adoption of spectral imaging and robotic guidance across European cancer centers, extending access to advanced minimally invasive treatments to a larger patient population.
The PreciseOnco project website will be available soon at www.preciseonco.eu.
The CORDIS project page for PreciseOnco can be accessed here.
References
[1] European Cancer Information System (ECIS) - jrc_CancerEstimates2022_factsheet.pdf.
[2] WorldHealth Organization (WHO) - Global cancer burden growing, amidst mounting need forservices.
[3] Global Interventional Oncology Market report - Interventional Oncology Market Size and Growth Analysis Report.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No. 101252582. The JU receives support from the European Union's Horizon Europe research andinnovation program and life science industries represented by COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. PreciseOnco is funded by the European Union, private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.